hydroxychloroquine has been researched along with Leukemia, Myeloid, Acute in 6 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Leukemia, Myeloid, Acute: Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, TM | 1 |
| Espitia, C | 1 |
| Wang, W | 1 |
| Nawrocki, ST | 1 |
| Carew, JS | 1 |
| Sieni, E | 1 |
| Pegoraro, F | 1 |
| Casini, T | 1 |
| Tondo, A | 1 |
| Bortone, B | 1 |
| Moriondo, M | 1 |
| Azzari, C | 1 |
| Galli, L | 1 |
| Favre, C | 1 |
| Patel, PA | 1 |
| Lapp, SA | 1 |
| Grubbs, G | 1 |
| Edara, VV | 1 |
| Rostad, CA | 1 |
| Stokes, CL | 1 |
| Pauly, MG | 1 |
| Anderson, EJ | 1 |
| Piantadosi, A | 1 |
| Suthar, MS | 1 |
| Khurana, S | 1 |
| Sabnis, HS | 1 |
| Folkerts, H | 1 |
| Hilgendorf, S | 1 |
| Wierenga, ATJ | 1 |
| Jaques, J | 1 |
| Mulder, AB | 1 |
| Coffer, PJ | 1 |
| Schuringa, JJ | 1 |
| Vellenga, E | 1 |
| Kim, Y | 2 |
| Eom, JI | 2 |
| Jeung, HK | 2 |
| Jang, JE | 1 |
| Kim, JS | 1 |
| Cheong, JW | 2 |
| Kim, YS | 1 |
| Min, YH | 2 |
6 other studies available for hydroxychloroquine and Leukemia, Myeloid, Acute
| Article | Year |
|---|---|
Moving beyond hydroxychloroquine: the novel lysosomal autophagy inhibitor ROC-325 shows significant potential in preclinical studies.
Topics: Animals; Antineoplastic Agents; Autophagy; Azacitidine; Carcinoma, Renal Cell; Cell Line, Tumor; Hyd | 2019 |
Favourable outcome of coronavirus disease 2019 in a 1-year-old girl with acute myeloid leukaemia and severe treatment-induced immunosuppression.
Topics: Antineoplastic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Female; Humans; Hydroxychl | 2020 |
Immune responses and therapeutic challenges in paediatric patients with new-onset acute myeloid leukaemia and concomitant COVID-19.
Topics: Adenosine Monophosphate; Adolescent; Alanine; Antimalarials; Antineoplastic Agents; Antiviral Agents | 2021 |
Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia.
Topics: Animals; Antigens, CD34; Apoptosis; Apoptosis Regulatory Proteins; Autophagy; Autophagy-Related Prot | 2017 |
Induction of cytosine arabinoside-resistant human myeloid leukemia cell death through autophagy regulation by hydroxychloroquine.
Topics: Antimetabolites, Antineoplastic; Autophagy; Cell Death; Cytarabine; Drug Resistance, Neoplasm; Human | 2015 |
Enhanced autophagy in cytarabine arabinoside-resistant U937 leukemia cells and its potential as a target for overcoming resistance.
Topics: Antimetabolites, Antineoplastic; Autophagy; Blotting, Western; Cytarabine; Drug Resistance, Neoplasm | 2016 |